[1] Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2016; 25(1): 16-27.
[2] Sharma KL, Rai R, Srivastava A, Sharma A, Misra S, Kumar A, et al. A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition. Tumour Biol. 2014; 35: 8597-8606.
[3] Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018; 21(3): 425-532.
[4] Gong FL, Wang L, Yu LG, Dang YF, Jiang XN1, Zhao L, et al. DHPAC, a novel microtubule depolymerizing agent, suppresses angiogenesis and vasculogenic mimicry formation of human non-small cell lung cancer. J Cell Biochem. 2020 Feb 14.
[5] Nienhüser H, Schmidt T. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. Int J Mol Sci. 2017; 19(1). pii: E43.
[6] Du H, Zhao J, Hai L, Wu J, Yi H, Shi Y. The roles of vasohibin and its family members: Beyond angiogenesis modulators. Cancer Biol Ther. 2017; 18(11): 827-832.
[7] Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H, Ohta H, et al. Vasohibin-1 expressed in endothelium of tumor vessels regulates angiogenesis. Am J Pathol. 2009; 175: 430-439.
[8] Wang Q, Tian X, Zhang C, Wang Q. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol. 2012; 29(4): 2727-36.
[9] Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012; 18(15): 4145-4153.
[10] Li D, Zhou K, Wang S, Shi Z, Yang Z. Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Sci. 2010; 101(2): 448–452.
[11] Kanomata N, Sato Y, Miyaji Y, Nagai A, Moriya T. Vasohibin-1 is a new predictor of disease-free survival in operated patients with renal cell carcinoma. J Clin Pathol. 2013; 66(7): 613-9.
[12] Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Int J Surg. 2010; 8(5): 336-41.
[13] Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
[14] Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-Analyses, http://www. ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed 15 December 2019.
[15] Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997; 127: 820-826.
[16] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
[17] Yu L, Mao X, Jiao Y, Song W, Wang D. Expression of vasohibin-1, MACC1 and KA11 proteins in serous ovarian cancer and their clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019; 44(12): 1344-1352.
[18] Yu L, Mao X, Wu S, Zhou L, Song W, Gong X, et al. The correlation of the expressions of WWOX, LGR5 and vasohibin-1 in epithelial ovarian cancer and their clinical significance. Int J Clin Exp Pathol. 2019; 12(1): 327-336.
[19] Ninomiya Y, Ozawa S, Oguma J, Kazuno A, Nitta M, Kajiwara H, et al. Expression of vasohibin-1 and -2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus. Oncol Lett. 2018; 16(4): 5265-5274.
[20] Wu SW, Wang YC, Ci HF, Tao YS. Expression of vasohibin-1 and MACC1 in lung squamous cell carcinoma and their clinicopathological significance. Nan Fang Yi Ke Da Xue Xue Bao. 2017; 37(7): 952-956.
[21] Ma D, Li J, Wang J, Sun Z, Wang K. Clinical implications of vasohibin-1 in esophageal carcinoma cells: Inhibition of cell growth and migration. Mol Med Rep. 2017; 16(2): 1479-1485.
[22] Sano R, Kanomata N, Suzuki S, Shimoya K, Sato Y, Moriya T, et al. Vasohibin-1 Is a Poor Prognostic Factor of Ovarian Carcinoma. Tohoku J Exp Med. 2017; 243(2): 107-114.
[23] Torii C, Hida Y, Shindoh M, Akiyama K, Ohga N, Maishi N, et al. Vasohibin-1 as a Novel Prognostic Factor for Head and Neck Squamous Cell Carcinoma. Anticancer Res. 2017; 37(3): 1219-1225.
[24] Mikami S, Oya M, Kosaka T, Mizuno R, Miyazaki Y, Sato Y, et al. Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients. Lab Invest. 2017; 97(7): 854-862.
[25] Shen Z, Yan Y, Ye C, Wang B, Jiang K, Ye Y, et al. The effect of Vasohibin-1 expression and tumor-associated macrophages on the angiogenesis in vitro and in vivo. Tumour Biol. 2016; 37(6): 7267-76.
[26] Liu S, Han B, Zhang Q, Dou J, Wang F, Lin W, et al. Vasohibin-1 suppresses colon cancer. Oncotarget. 2015; 6(10): 7880-7898.
[27] Murakami K, Kasajima A, Kawagishi N, Sekiguchi S, Fujishima F, Watanabe M, et al. The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma. Hum Pathol. 2014; 45(3): 589-97.
[28] Yan Y, Shen Z, Ye Y, Jiang K, Zhang H, Shen C, et al. A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1. Med Oncol. 2014; 31(2): 816.
[29] Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D, et al. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol. 2014; 31(5): 963.
[30] Kitajima T, Toiyama Y, Tanaka K, Saigusa S, Kobayashi M, Inoue Y, et al. Vasohibin-1 increases the malignant potential of colorectal cancer and is a biomarker of poor prognosis. Anticancer Res. 2014; 34(10): 5321-5329.
[31] Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 2013; 108(10): 2123-2129.
[32] Kanomata N, Sato Y, Miyaji Y, Nagai A, Moriya T. Vasohibin-1 is a new predictor of disease-free survival in operated patients with renal cell carcinoma. J Clin Pathol. 2013; 66(7): 613-9.
[33] Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012; 18(15): 4145-4153.
[34] Wang Q, Tian X, Zhang C, Wang Q. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol. 2012; 29(4): 2727-2736.
[35] Sato Y. Double-Face of Vasohibin-1 for the Maintenance of Vascular Homeostasis and Healthy Longevity. J Atheroscler Thromb. 2018; 25(6): 461-466.
[36] Takeda E, Suzuki Y, Yamada T, Takagiri H, Sato Y. Knockout of vasohibin-1 gene in mice results in healthy longevity with reduced expression of insulin receptor, insulin receptor substrate 1, and insulin receptor substrate 2 in their white adipose tissue. J Aging Res. 2017; 2017: 9851380.
[37] Zhou CF, Ma J, Huang L, Yi HY, Zhang YM, Wu XG, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 2019; 38(8): 1256-1268.
[38] Watanabe T, Hosaka T, Ohmori-Matsuda K, Suzuki Y, Suzuki H, Yabuki H, et al. High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma. Health Sci Rep. 2018; 1(6): e40.
[39] Cao L, Sun PL, He Y, Yao M, Gao H. Desmoplastic Reaction and Tumor Budding in Cervical Squamous Cell Carcinoma are Prognostic Factors for Distant Metastasis: A Retrospective Study. Cancer Manag Res. 2020; 12: 137-144.
[40] Zhang B, Wu Z, Xie W, Tian D, Chen F, Qin C, et al. The expression of vasohibin-1 and its prognostic significance in bladder cancer. Exp Ther Med. 2017; 14(4): 3477-3484.
[41] Li D, Zhou K, Wang S, Shi Z, Yang Z. Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Sci. 2010; 101: 448-452.
[42] den Uil SH, van den Broek E, Coupé VMH, Vellinga TT, Delis-van Diemen PM, Bril H, et al. Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study. BMC Gastroenterol. 2019; 19(1): 146.
[43] Miyata Y, Mitsunari K, Asai A, Takehara K, Mochizuki Y, Sakai H. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy. Prostate. 2015; 75(1): 84-91.
[44] Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, Yoshinaga K, et al. Vasohibin-1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis. Cancer Sci. 2009; 100: 88–94.
[45] Saito M, Suzuki Y, Yano S, Miyazaki T, Sato Y. Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. J Biochem. 2016; 160: 227-232.
[46] Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 2009; 113(19): 4810-4818.
[47] Sato Y. Novel link between inhibition of angiogenesis and tolerance to vascular stress. Journal of Atherosclerosis and Thrombosis. 2015; 22: 327-334.
[48] Hantelys F, Godet AC, David F, Tatin F1, Renaud-Gabardos E1, Pujol F, et al. Vasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation in early hypoxia. Elife. 2019; 8. pii: e50094.